Trellis Bioscience
PrivateLast Round
Series C
Jul 16, 2026
Total Funding Raised
$50.54M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Trellis Bioscience operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series C round in July 2026.
Trellis Bioscience is a biotechnology company that develops native human monoclonal antibody therapies for infectious diseases and cancer using its proprietary CellSpot™ discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trellis Bioscience Comparables
Compare Trellis Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Peptilogics | 83% | |
| Clarametyx Biosciences | 81% | |
| Aridis Pharmaceuticals, Inc. | 81% |
For institutional investors. Book with your work email.
Trellis Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 16, 2026 | ||||
| Series C | Jan 30, 2026 | ||||
| VC Round | Oct 22, 2024 | ||||
| Grant | Jul 18, 2024 | ||||
| Seed | Apr 20, 2023 | ||||
Seed | Jun 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Trellis Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pac-Link Bio Venture Investment Corporation | Series B |
| AMR Action Fund | Series C |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| Sagamore Bioventures LLC | Series B |
| Easton-Hunt Capital Partners, L.P. | Series A, Series B, Series C |
| Nodenza Venture Partners | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 72% MoM.
- Jul 16, 2026
$9M round led by Easton-Hunt Capital Partners.
For institutional investors. Book with your work email.
Trellis Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Trellis Bioscience's valuation, stock price, and market status.
Is Trellis Bioscience a public or private company?
Trellis Bioscience is a private company.
What is the current stock price of Trellis Bioscience?
Trellis Bioscience is a private company, so its shares have no public market price. Caplight tracks Trellis Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Trellis Bioscience worth (valuation)?
Valuation information for Trellis Bioscience is not publicly available.
Can I buy Trellis Bioscience stock?
Trellis Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Trellis Bioscience's last funding round?
Trellis Bioscience's most recent funding round was Series C on July 16, 2026.
Who are the main investors in Trellis Bioscience?
Key investors in Trellis Bioscience include National Institute of Allergy and Infectious Diseases, CARB-X, Easton-Hunt Capital Partners, L.P., Nodenza Venture Partners.
Will Trellis Bioscience IPO soon?
No public IPO plans have been announced for Trellis Bioscience.
How can I track Trellis Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Trellis Bioscience's shares on secondary markets.